Clin2
NCT06907069Possibly a fitEnrolling by invitation

Combined treatment for drug-resistant bacteria in lung infections

Lung Infection Bacterial

Part of Lungs & breathing clinical trials.

This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
200 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old
  • You have a lung infection acquired in the hospital or from a breathing machine
  • The infection is caused by a type of bacteria that is resistant to common strong antibiotics but may respond to colistin
  • You have not had a severe allergic reaction to colistin or similar drugs
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06834971Recruiting
Inhaled colistin to prevent pneumonia in ventilated patients

This trial tests if inhaling a medication called colistin can prevent ventilator-associated pneumonia (a lung infection) in patients who are on a breathing machine. It aims to reduce the risk for those at high risk of getting an infection from drug-resistant bacteria.

Jinan, Shandong
NCT07865871Not yet recruiting· Early Phase 1
Inhaled antibiotic for drug-resistant pneumonia after stroke

This study tests whether adding an inhaled antibiotic (polymyxin) to standard IV antibiotics helps treat a severe lung infection that is resistant to many drugs. It is for people who had a stroke and developed this infection while on a breathing machine. The inhaled drug is delivered directly to the lungs, which might improve treatment and reduce side effects.

NCT07512596Recruiting· Phase 2
Study of a new antibiotic for hospital pneumonia from resistant bacteria

This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.

Bengbu, Anhui
NCT07004049Recruiting· Phase 4
Testing combinations for resistant Gram-negative infections

This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.

Brisbane, Queensland
NCT06488794Not yet recruiting· Phase 2/Phase 3
Nebulized antibiotic to prevent pneumonia in children on ventilators

This trial tests whether giving a nebulized (inhaled) antibiotic called colistimethate sodium can prevent ventilator-associated pneumonia (a lung infection) in children who are on a breathing machine. If it works, this could reduce the risk of serious lung infections in hospitalized children.

NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia

This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.

Fuzhou, Fujian

Hear when a new Lung Infection Bacterial trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.